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 We report a case of 29-year-old Japanese female with a 
history of resection of primary carcinoma of the right 
breast. After a partial response by chemotherapy with 
pirarubicin and docetaxel for lung metastasis, the patient 
developed multiple brain and bone metastases. As the de-
gree of overexpression of human epidermal growth factor 
receptor-2 (HER2) was (2+), trastuzumab was administered 
in combination with paclitaxel. Asymptomatic left ven-
tricular (LV) systolic dysfunction evaluated by echocardi-
ography was observed ten weeks after the beginning of the 
treatment. After two weeks of discontinuation of the ther-
apy, however, LV function showed rapid recovery and the 
resumed use of trastuzumab did not cause further cardiac 
deterioration. The patient died of sudden respiratory fail-
ure due to cerebral herniation and not to heart failure. 
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therapy has proved effective and well tolerated in pa-
tients with HER2-positive metastatic breast cancer." 
Retrospective analysis revealed that infusion-related 
reactions and cardiotoxicity emerged as the two main 
safety concerns with the use of trastuzumab. The inci-
dence of serious adverse effects attributable to 
trastuzumab was low, however, the occurence of car-
diac toxicity was high especially in patients previ-
ously or concomitantly treated with anthracyclines.2' 
Clinical use of trastzumab has become available since 
June 2001 in Japan. We herein describe a Japanese pa-
tient with progressive metastatic breast cancer who 
showed a mild systolic dysfunction evaluated by echo-
cardiogram during the administration of trast-Lizurnab.
Case Report
Key Words: trastuzumab, anthracyclines, human epidermal 
            growth factor receptor-2, paclitaxel, echocardio-
           gram, LV systolic dysfunction
Introduction
 Trastuzumab (Herceptin) is a humanized anti-human 
epidermal growth factor-2 (HER2) monoclonal anti-
body which was approved by the United States Food 
and Drug Administration (FDA) in September 1998, 
and more than 25,000 patients have been treated. This
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 A 29-year-old female was introduced to our outpa-
tient clinic for evaluating the basic cardiac function 
before the use of trastuzumab. 
 The patient visited our hospital because of right 
breast mass and was diagnosed as a breast cancer 
(T1aN1M0, Stage I) on December 25, 1998. The results 
of a quantitative analysis of estrogen receptors and 
progesterone receptors in the specimen were negative. 
After resection of primary tumor, the patient under-
went radiation therapy (50 Gy), followed by chemo-
therapy consisting of pirarubicin 20 mg/month for 
three months because of high chemosensitiveness by 
MTT assay. 
 On May 9, 2001, lung metastasis (Fig.1) was de-
tected and the patient was given six courses of che-
motherapy consisting of pirarubicin 30 mg/month and 
docetaxel 80 mg/month. However, multiple brain and 
bone metastases were detected by brain magnetic 
resonance image (November 14, 2001) (Fig. 2A,B) and
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Fig. 1. Chest roentgenogram performed on May 18, 2001 
showing infiltrative shadow in bilateral lower lobes, suggest-
ing lung metastases.
bone scintigraphy (October 31, 2001) (Fig. 3A) respec-
tively. Radiation therapy could not be continued be-
cause of the increase of brain edema. 
Immunohistochemical staining for the HER2 was mod-
erately positive on the surface of primary tumor cells 
(referred to as a score of 2+), therefore trastuzumab 2 
mg/kg/week was administered in combination with
Fig. 2. Brain magnetic resonance images of enhanced coronal 
T1-weighted images (A, C) and axial T2-weighted images (B, 
D). Upper panels (A, B) performed on November 14, 2001 
showing meningeal dissemination, multiple cerebellar, cerebral, 
and brainstem metastases. The number and size of brain me-
tastases were not changed (C), however, an edema of cerebellar 
hemisphere was slightly reduced on January 16, 2002 (D).
paclitaxel 300 mg/month on November 21, 2001. The 
patient showed partial response transiently because 
the uptake of right 11th rib and the edema of
Fig. 3. 99mTc-HMDP bone scintigraphy performed October 31, 2001 demonstrating an intense uptake at right 7th and 11th ribs, 
moderate uptake at right sacroiliac joint and left iliac wing, suggesting bone metastases (A). The uptake of right 11th rib was 
decreased on January 17, 2002 (B).
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Fig. 4. Transthoracic echocardiogram performed (A) just be-
fore the beginning of the administration of trastuzumab 
(LVDd, 45 mm; LVDs, 27 mm; LVEF, 70%; FS, 40%), (B) 10 
weeks after the administration of trastuzumab (LVDd, 49 
mm; LVDs, 33 mm; LVEF, 61%; FS, 33%), (C) 2 weeks after 
discontinuation of the administration of trastuzumab (LVDd, 
48 mm; LVDs, 31 mm; LVEF, 65%; FS, 36%), and (D) resumed 
use of trastuzumab, a week before her death (LVDd, 45 mm; 
LVDs, 29 mm; LVEF, 65%; FS, 36%). EF: ejection fraction, FS: 
fractional shortening, LVDd: left ventricular diastolic dimen-
sion, LVDs: left ventricular systolic dimension.
cerebellar hemisphere were reduced (Fig. 2C,D, 3B). 
 Echocardiogram performed just before the use of 
trastuzumab showed left ventricular diastolic dimen-
sion (LVDd): 45 mm, left ventricular systolic dimen-
sion (LVDs): 27 mm, and left ventricular ejection frac-
tion (LVEF): 70%, fractional shortening (FS): 40% 
(Fig.4A). Ten weeks after the beginning of treatment 
with trastuzumab and paclitaxel, LV systolic fuction 
was declined; LVDd: 49 mm, LVDs: 33 mm, LVEF: 
61%, FS: 33% (Fig.4B) although the patient had no 
symptoms of heart failure. Two weeks of discontinua-
tion of the combined chemotherapy, LV function 
showed partial recovery; LVDd: 48 mm, LVDs: 31 mm, 
LVEF: 65%, FS: 36% (Fig.4C). Then we resumed com-
bined chemotherapy and her LV function did not 
show a further deterioration; LVDd: 45 mm, LVDs: 29 
mm, LVEF: 65%, FS: 36% (Fig.4D). 
 On April 10, 2002, twenty weeks after the initial ad-
ministration of trastuzumab, the patient died of sud-
den respiratory failure due to cerebral herniation. 
Autopsy was not performed because permission was 
not obtained.
Discussion
  Trastuzumab (Herceptin), an IgG monoclonal anti-
bodies against the extracellular domain of the HER-2, 
has proved to increase the clinical benefit of first-line 
chemotherapy in metastatic breast cancer that 
overexpresses HER2. Trastuzumab demonstrated en-
hanced anti-tumor activity when used in combination 
with cisplatin, doxorubicin, and especially paclitaxel in 
preclinical models."' From a phase III clinical trial, 
paclitaxel response rate was significantly improved in 
patients with breast cancer when erbB2 was 
downregulated by trastuzumab.' Long-term survival 
of women with congestive heart failure (6 years, 33%)' is 
superior to that of women with breast cancer and dis-
tant metastases (5 years, 22%)` , yet it is far worse 
than that of women with breast cancer and regional 
metastases (5 years, 77%)` or women without identifi-
able metastases (5 years, 97%)` . Moreover most 
women who developed heart failure after trastuzumab 
administration showed symptomatic improvement with 
appropriate therapy' . At this moment, we have no op-
tion but to try trastuzumab for her advanced metastatic 
breast cancer. Before the use of this therapeutic anti-
bodies, genotyping tumor samples for the expression 
of HER-2 (based on a 0-3+ scale) is required. Our pa-
tient fortunately showed the 2+ level of overexpression 
of HER-2 in her tumor samples (Fig.5), therefore ad-
ministration of trastuzumab in combination with 
paclitaxel was commenced and at least transiently, 
partial respose was achieved. 
 Cardiac dysfunction was an unfavorable and serious 
side effect of trastuzumab. The incidence was greatest
Fig. 5. Immunohistochemical staining for the HER2 gene 
product was moderately positive (score 2+) on the primary 
tumor cell membrane (x200). HER2: human epidermal growth 
factor receptor-2.
in patients receiving trastuzumab and anthracycline 
plus cyclophosphamide concomitantly (27%). The risk 
was substantially lower in patients receiving paclitaxel 
and trastuzumab (13%) or trastuzumab alone (5%).2 
HER2 overexpression has been associated with the de-
velopment of breast cancer, however HER2 receptors 
themselves seem to be cardioprotective because they 
mediate the activation of cardiac survival pathways 
and trastuzumab increases susceptibility of myofilaments 
to doxorubicin. s' Using ventricular-restricted ErbB2 de-
ficient mice, Crone et al. demonstrated that ErbB2 sig-
naling in cardiomyocytes was essential for the preven-
tion of dilated cardiomyopathy. < 
 The cardiac review and evaluation committee (CREC) 
was established to obtain independent and unbiased 
estimates of cardiac dysfunction risk for patients re-
ceiving trastuzumab. According to CREC criteria, car-
diac LVEF data for low absolute values (<50%) or sig-
nificant decrease (>20% relative to baseline) was used 
as cardiac dysfunction. And the CREC also established 
following criterion to confirm or revise a preliminary 
diagnosis of cardiac dysfunction as; decline in LVEF 
of at least 5% to less than 55% with accompanying 
signs or symptoms of congestive heart failure, or a de-
cline in LVEF of at least 10% to below 55% without 
accompanying signs or symptoms. Our patient demon-
strated mild systolic LV dysfunction (12.9% decrese in 
LVEF) associated with LV dilatation evaluated by 
echocardiography after 10 weeks treatment with 
trastuzumab and paclitaxel. in this case, decline of 
LVEF and dilatation of LVDd after treatment of 
trastuzumab were small, which did not satisfy CREC 
criteria of cardiac dysfunction. And yet it potentially 
possessed variability problem, although recording of 
echocardiogram was performed by the same doctor. 
Biological markers such as brain natriuretic peptide or 
troponin T might be a sensitive and specific markers 
of trastuzumab-induced cardiac dysfuction, although 
the usefulness of them has not been defined. 
 Unfortunately, we could not continue a long-term 
follow up because the patient suddenly died of cere-
bral herniation. Our patient showed a partial improve-
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ment of LV systolic function after two weeks discon-
tinuation of trastuzumab administration. Moreover, one 
week before her death, echocardiography did not dem-
onstrate a further deterioration of LV systolic funcftion, 
despite the fact that the administration of trastuzurnab 
and paclitaxel was resumed. It was reported that 
trastuzumab was discontinued because cardiac dys-
function had been observed in 18 out of 235 patients 
(8%) overall, and most of these patients received an 
anthracyclines, cyclophosphamide, and trastuzumab.9 
These suggest that trastuzumab plus previous use of 
anthracycline may be related to LV dysfunction in this 
case. It is imperative that physicians perform long-term 
follow-up of the patient who is receiving trastuzurnab, 
especially one who is given anthracyclines previously 
or simultaneously, by evaluating LV systolic function 
by echocardiogram noninvasively.
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